# Next&Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/next-bio

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.nextandbio.com
- Total disclosed funding: $5.2M
- Latest round: Series A (Apr 3, 2020)
- Investors on record: 5

## About

Next&Bio, based in South Korea, specializes in developing anti-drug resistance solutions through patient-derived organoids, enhancing personalized medicine and facilitating advanced drug testing methodologies.Founded in 2018 and headquartered in Seoul, South Korea, Next&Bio develops patient-derived organoids for drug testing and molecular diagnostics. The company has successfully raised KRW 6.5 billion in Series A funding from notable investors including HK Inno.N Corporation and Hyundai Investment Partners. The firm has completed one deal as of April 2020, led by CEO Hyeon-sook Lee.NEXT&BIO specializes in the development and provision of patient-derived organoids aimed at enabling personalized treatment methods. Their core offerings focus on organoid drug testing and molecular diagnostics, which provide high-precision disease models tailored to the specific needs of pharmaceutical companies, patients, and hospitals. By utilizing organoids, NEXT&BIO addresses critical challenges in drug development and validation, delivering more accurate and reliable results for therapeutic efficacy. The company’s products are utilized primarily in major markets including North America, Europe, and parts of Asia, where they cater to a diverse clientele consisting of biotech firms, research institutions, and healthcare providers.NEXT&BIO's revenue model is structured around B2B transactions, where pharmaceutical companies and healthcare institutions partner with the firm to access its organoid testing services and disease models. The business transactions typically involve structured agreements that facilitate access to these high-value products tailored for drug development and clinical research. The company engages in direct sales and partnerships with clients, providing specific pricing plans correlated with the scale and complexity of the services rendered, including tiered pricing based on the volume of organoid samples or the scope of diagnostic testing required.In April 2020, Next&Bio raised KRW 6.5 billion in Series A funding to enhance its Contract Research Organization (CRO) services. The company plans to expand its offerings and develop new products aimed at improving patient-derived organoid technologies. Future market expansion is targeted at increasing presence in North America and Europe by 2023, thereby enhancing its reach in the pharmaceutical and healthcare sectors.

## Funding rounds

- Series A, Apr 3, 2020, $5.2M — Hyundai Venture Investment, Hyundai Investment Partners, Kolmar Korea, HK Inno.N Corporation, Stonebridge Ventures

## Investors

- Hyundai Venture Investment (https://capitalatlas.ai/funds/hyundai-venture-investment) — Series A
- Hyundai Investment Partners (https://capitalatlas.ai/funds/hyundai-investment-partners) — Series A
- Kolmar Korea — Series A
- HK Inno.N Corporation — Series A
- Stonebridge Ventures — Series A